期刊
CANCER GENE THERAPY
卷 18, 期 5, 页码 326-335出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/cgt.2010.82
关键词
immunotherapy; breast cancer; HER2/neu; Adenovirus vector; Ad5
类别
资金
- NIH-NCI [1R43CA139663-01]
Immunotherapy is a promising approach for the treatment of cancers. Modified adenovirus 5 (Ad5) vectors have been used as a platform to deliver genes encoding tumor associated antigens (TAA). A major obstacle to Ad5 vector immunotherapy has been the induction of vector immunity following administration or the presence of pre-existing Ad5 immunity, which results in vector mitigation. It has been reported by us that the Ad5[E1-, E2b-] platform with unique deletions in the E1, E2b and E3 regions can induce potent cell mediated immunity (CMI) against delivered transgene products in the presence of pre-existing Ad5 immunity. Here we report the use of an Ad5[E1-, E2b-] vector platform expressing the TAA HER2/neu as a breast cancer immunotherapeutic agent. Ad5[E1-, E2b-]-HER2/neu induced potent CMI against HER2/neu in Ad5 naive and Ad5 immune mice. Humoral responses were also induced and antibodies could lyse HER2/neu expressing tumor cells in the presence of complement in vitro. Ad5[E1-, E2b-]-HER2/neu prevented establishment of HER2/neu-expressing tumors and significantly inhibited progression of established tumors in Ad5 naive and Ad5 immune murine models. These data demonstrate that in vivo delivery of Ad5[E1-, E2b-]HER2/neu can induce anti-TAA immunity and inhibit progression of HER2/neu expressing cancers. Cancer Gene Therapy (2011) 18, 326-335; doi:10.1038/cgt.2010.82; published online 14 January 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据